FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials. PMID 41684244 · J Antimicrob Chemother · 2026-Feb-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study. PMID 41676981 · J Antimicrob Chemother · 2026-Feb-02 Study is a Phase IV randomized controlled trial of an antiretroviral regimen for HIV infection, not oncology. No primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) is reported. Primary outcome is 'treatment failure' defined by virological failure, discontinuation, or loss to follow-up, which is not a standard oncology time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Self-Acupressure for Fatigue in Patients Surviving Ovarian Cancer: A Randomized Clinical Trial. PMID 41642626 · JAMA Netw Open · 2026-Feb-02 Study is a randomized, phase 3 trial in human ovarian cancer survivors, but the intervention is self-acupressure (non-drug), and the primary efficacy endpoint is change in fatigue score (not a time-to-event endpoint like OS, PFS, DFS, etc.). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian cancer: a phase 3, double-blind, parallel group, randomized controlled pilot study. PMID 41630017 · BMC Med · 2026-Feb-02 The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, it fails the critical time-to-event endpoint criterion. The primary endpoint is an incidence measure, not a time-to-event outcome. While survival was a secondary endpoint, the results do not include Kaplan-Meier survival analyses or hazard ratios, and the abstract only states no difference in survival without providing the necessary time-to-event evidence. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Phase III triple-blind randomised placebo-controlled trial to evaluate effectiveness of early treatment with pregabalin to reduce pain severity after whiplash road traffic injury: study protocol for the PRioRTI Trial {1}. PMID 41629976 · Trials · 2026-Feb-02 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Fecal incontinence after prostate cancer irradiation: a systematic literature review. PMID 41629638 · Prostate Cancer Prostatic Dis · 2026-Feb-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial. PMID 41629265 · Signal Transduct Target Ther · 2026-Feb-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| ctDNA guided immunotherapy in patients with advanced non-small cell lung cancer: a nationwide Danish, randomised, intervention study (PRELUCA-PRediction in LUng CAncer Treatment) - study protocol. PMID 41628935 · BMJ Open · 2026-Feb-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Shortened High-dose Palliative Radiotherapy for Lung Cancer (SHiP-Rt): protocol for a single-arm, multicentre, phase II study. PMID 41628919 · BMJ Open · 2026-Feb-02 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial. PMID 41266255 · J Nucl Med · 2026-Feb-02 The study is a human oncology Phase 3 randomized trial with original results. However, it is ineligible because the intervention is a diagnostic/imaging procedure (PSMA-targeted PET/MRI-guided biopsy) with no drug-containing therapeutic intervention, and the primary outcomes are diagnostic accuracy metrics (sensitivity, specificity, PPV, NPV) rather than time-to-event efficacy endpoints. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials. PMID 40929381 · Eur Heart J Cardiovasc Pharmacother · 2026-Feb-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study. PMID 41738096 · Am J Respir Crit Care Med · 2026-Feb-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Evaluation of oncologic safety and clinical effectiveness of immediate autologous fat grafting in breast-conserving surgery: a multicenter, prospective, randomized controlled clinical trial for breast cancer. PMID 41731868 · Int J Surg · 2026-Feb-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis. PMID 41661214 · JAMA Neurol · 2026-Feb-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Clascoterone Cream 1% for Acne Are Independent of Age and Sex. PMID 41642149 · J Drugs Dermatol · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Mixed-Methods to Define Meaningful Change using Exit Interviewand Clinical Trial Data in Patients with Tenosynovial Giant Cell Tumor (TGCT). PMID 41621028 · Qual Life Res · 2026-Feb-01 The record describes a methodological sub-study embedded within the Phase 3 MOTION trial. It does not present the primary or key secondary time-to-event efficacy results (e.g., OS, PFS) of the trial. The analysis focuses on defining responder thresholds for non-time-to-event clinical outcome assessments. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Analysis of quality-adjusted survival time without symptoms or toxicity for pembrolizumab plus chemotherapy as treatment for previously untreated participants with advanced or metastatic esophageal cancer. PMID 41620988 · Qual Life Res · 2026-Feb-01 The record is a formal result of a randomized trial (KEYNOTE-590) with a drug intervention and a primary/key secondary time-to-event endpoint (OS, PFS). However, the specific analysis reported is a secondary, pre-specified health-related quality of life (Q-TWiST) analysis, which is not a primary efficacy endpoint per the eligibility criteria. The publication type 'Randomized Controlled Trial' does not confirm Phase III/IIIb or Phase II/III status, but the trial is a large, definitive randomized study. The analysis itself is a secondary endpoint analysis focused on quality of life, making it ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Intrathecal Morphine for Enhanced Recovery After Laparoscopic Colorectal Surgery: A Randomized Clinical Trial. PMID 41433024 · JAMA Surg · 2026-Feb-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial. PMID 41411005 · JAMA Ophthalmol · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial. PMID 41379459 · JAMA Oncol · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical Trials. PMID 41343184 · JAMA Otolaryngol Head Neck Surg · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. PMID 41343176 · JAMA Oncol · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The Portable Transcranial Electrical Stimulation and Internet-Based Behavioral Therapy for Major Depression Study (PSYLECT): Results of the maintenance phase. PMID 41284536 · J Affect Disord · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Trajectories and predictors of depressive and anxiety symptom improvement with adjunctive cariprazine in antidepressant-treated adults with major depression: A Bayesian mega-analysis of two randomized trials. PMID 41224012 · J Affect Disord · 2026-Feb-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. PMID 41189315 · Neuro Oncol · 2026-Feb-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Elective versus involved target volume definition of stereotactic spine radiosurgery for spinal metastases: A phase II randomized clinical trial. PMID 41143555 · Neuro Oncol · 2026-Feb-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease Risk Score Model after Continuing or Switching to a Doravirine-Based HIV Treatment Regimen. PMID 41081774 · J Acquir Immune Defic Syndr · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial. PMID 41037024 · AIDS · 2026-Feb-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study. PMID 41033612 · Int J Radiat Oncol Biol Phys · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiation Therapy for Cervical Cancer: A Phase 3 Prospective Multicenter Randomized Controlled Trial. PMID 40876576 · Int J Radiat Oncol Biol Phys · 2026-Feb-01 The trial meets criteria for oncology, human, randomized, and phase 3, and reports primary results. However, it is ineligible because the intervention is a non-drug hydrogel, and the primary endpoint is a dosimetric measure, not a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparing Precutting Endoscopic Mucosal Resection Using Snare-Tip and Endoscopic Submucosal Dissection Knife for Large Nonpedunculated Colorectal Polyps: A Randomized Controlled Trial. PMID 40367489 · Am J Gastroenterol · 2026-Feb-01 The record is excluded because it does not meet the 'drug intervention' and 'time_to_event' criteria. The study compares procedural techniques (snare-tip vs. ESD knife) for endoscopic resection of colorectal polyps, which is a non-drug intervention. The primary efficacy endpoint (en bloc resection rate) is not a time-to-event outcome. Therefore, it is ineligible for the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ligation site of the inferior mesenteric vein in laparoscopic radical resection of rectal cancer: a study protocol for a multicenter randomized-controlled trial. PMID 42147431 · Gastroenterol Rep (Oxf) · 2026-Feb 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 Q-TWiST analysis. PMID 41964430 · Immunotherapy · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cefepime-enmetazobactam for complicated urinary tract infections: Redefining ESBL therapy. PMID 41949135 · Indian J Med Res · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of the Granulocyte Colony-Stimulating Factor in Sepsis-Associated Immunosuppression: An Open-Label Randomized Controlled Trial. PMID 41883885 · Cureus · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Randomized, Multicenter Study Evaluating the Efficacy, Safety and Tolerability of Dapagliflozin + Gliclazide Fixed Dose Combination Over Dapagliflozin Monotherapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Metformin Monotherapy. PMID 41859618 · Cureus · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of direct oral anticoagulants in pediatric oncology patients: real-world data from two quaternary care pediatric centers. PMID 41853582 · Res Pract Thromb Haemost · 2026-Feb This is a retrospective cohort study (non-randomized) of direct oral anticoagulants in pediatric oncology patients. While it is oncology, human, and reports original results on a drug intervention, it lacks the required randomized controlled trial design (Phase III/IIIb or II/III) and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR analysis. The primary endpoints are safety (bleeding) and efficacy (recurrent thrombosis), which are event rates, not time-to-event outcomes. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cardiovascular Outcomes Associated With Biologic Therapy in Inflammatory Dermatologic Diseases: A Systematic Review. PMID 41822639 · Cureus · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Bridging paradigms and shaping the future of resectable gastric cancer: a narrative review of the post-MATTERHORN era. PMID 41809424 · Gastroenterol Rep (Oxf) · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Interim analysis of short-term outcomes between robotic and laparoscopic surgery for colon cancer: results from the ESSIMIC trial. PMID 41802309 · Ann Coloproctol · 2026-Feb 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Evaluating the Effect of Acceptance and Commitment Therapy on Post-traumatic Growth in Cancer Survivors: A Pilot Non-randomized Controlled Trial in a Greek Sample. PMID 41798432 · Cureus · 2026-Feb The study is a non-randomized, pilot trial of a psychotherapy intervention for cancer survivors. It does not meet the core criteria of being a randomized trial of a drug intervention with a time-to-event primary efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ethical considerations in randomization for neurosurgical oncology trials: A scoping review. PMID 41798128 · Neurooncol Pract · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Aetiology of sepsis in adults living with HIV in East Africa: a secondary analysis of an open-label, multicentre, randomised, controlled phase 3 trial. PMID 41768988 · EClinicalMedicine · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Intravenous lidocaine for gastrointestinal recovery after colorectal surgery: the ALLEGRO placebo-controlled randomised trial and cost-effectiveness analysis. PMID 41731962 · Health Technol Assess · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Interim Results from a Randomized Trial. PMID 41726013 · Indian J Surg Oncol · 2026-Feb The trial is oncology, human, randomized, and includes a drug intervention, but it lacks the required time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR analysis. The primary outcome is pCR, and distant metastasis is reported as a count, not a time-to-event. Phase is not definitively established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [CAR-T cell immunotherapy in early relapse after introduction chemoimmunotherapy]. PMID 41716107 · Recenti Prog Med · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Effect of Audiovisual Education on Breast Cancer Screening and Fear Among Illiterate Women: A Double-Blind Randomised Controlled Trial. PMID 41709589 · J Eval Clin Pract · 2026-Feb Study is a randomized trial on breast cancer screening education, which is oncology-related and in humans. However, it lacks a drug intervention (the intervention is audiovisual education) and does not report a time-to-event efficacy endpoint. Therefore, it does not meet the core criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial. PMID 41705515 · Mult Scler · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The effect of two remote exercise programs on cardiorespiratory fitness, cardiac function, and vascular health in patients with breast cancer. PMID 41704018 · Physiol Rep · 2026-Feb The study is an oncology RCT in humans reporting original primary results, but it is excluded because: 1) The intervention is exercise-only (no drug-containing intervention), and 2) The endpoint is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or any analysis involving Kaplan-Meier or HR). The endpoints measured are physiological (VO2peak, biomarkers). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Disparities in Distress Symptoms Among Cancer Inpatients, Outpatients and Relatives Through Introducing and Evaluating Digital Distress Screening. PMID 41689782 · Psychooncology · 2026-Feb The study is a randomized controlled trial in oncology patients, but it evaluates digital screening tools for distress, not a drug intervention. It does not have a Phase III/IIIb or Phase II/III designation. The primary endpoints are distress levels, usability, and acceptance, not time-to-event efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |